{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:15:41Z","timestamp":1792034141457,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["275525, 284663"],"award-info":[{"award-number":["275525, 284663"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["278741, 271845"],"award-info":[{"award-number":["278741, 271845"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005431","name":"Finnish Cultural Foundation | Pirkanmaan Rahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EVO"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glucocorticoids are routinely used in the clinic as anti-inflammatory and immunosuppressive agents as well as adjuvants during cancer treatment to mitigate the undesirable side effects of chemotherapy. However, recent studies have indicated that glucocorticoids may negatively impact the efficacy of chemotherapy by promoting tumor cell survival, heterogeneity, and metastasis. Here, we show that dexamethasone induces upregulation of ROR1 expression in ovarian cancer (OC), including platinum-resistant OC. Increased ROR1 expression resulted in elevated RhoA, YAP\/TAZ, and BMI-1 levels in a panel of OC cell lines as well as primary ovarian cancer patient-derived cells, underlining the translational relevance of our studies. Importantly, dexamethasone induced differentiation of OC patient-derived cells ex vivo according to their molecular subtype and the phenotypic expression of cell differentiation markers. High-throughput drug testing with 528 emerging and clinical oncology compounds of OC cell lines and patient-derived cells revealed that dexamethasone treatment increased the sensitivity to several AKT\/PI3K targeted kinase inhibitors, while significantly decreasing the efficacy of chemotherapeutics such as taxanes, as well as anti-apoptotic compounds such as SMAC mimetics. On the other hand, targeting ROR1 expression increased the efficacy of taxane drugs and SMAC mimetics, suggesting new combinatorial targeted treatments for patients with OC.<\/jats:p>","DOI":"10.1038\/s41419-020-03009-4","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T16:05:06Z","timestamp":1601309106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-0709","authenticated-orcid":false,"given":"Hanna","family":"Karvonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariliina","family":"Arjama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kaleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmiina","family":"Niininen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-2522","authenticated-orcid":false,"given":"Harlan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Koivisto-Korander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Pakarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Lassus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Loukovaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Murum\u00e4gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ungureanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"3009_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7\u201330 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"3009_CR2","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright, A. A. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 34, 3460\u20133473 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3009_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"3009_CR4","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","volume":"27","author":"DM Gershenson","year":"2016","unstructured":"Gershenson, D. M. Low-grade serous carcinoma of the ovary or peritoneum. Ann. Oncol. 27, i45\u2013i49 (2016).","journal-title":"Ann. Oncol."},{"key":"3009_CR5","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","volume":"31","author":"S Yennurajalingam","year":"2013","unstructured":"Yennurajalingam, S. et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J. Clin. Oncol. 31, 3076\u20133082 (2013).","journal-title":"J. Clin. Oncol."},{"key":"3009_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12672-017-0319-0","volume":"9","author":"V Djedovic","year":"2018","unstructured":"Djedovic, V., Lee, Y.-Y., Kollara, A., May, T. & Brown, T. J. The two faces of adjuvant glucocorticoid treatment in ovarian cancer. Horm. Cancer 9, 95\u2013107 (2018).","journal-title":"Horm. Cancer"},{"key":"3009_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ijc.21743","volume":"119","author":"M Sui","year":"2006","unstructured":"Sui, M., Chen, F., Chen, Z. & Fan, W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int. J. Cancer 119, 712\u2013717 (2006).","journal-title":"Int. J. Cancer"},{"key":"3009_CR8","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-08-2131","volume":"15","author":"A Melhem","year":"2009","unstructured":"Melhem, A. et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1\/DUSP1 in ovarian tissues. Clin. Cancer Res. 15, 3196\u20133204 (2009).","journal-title":"Clin. Cancer Res."},{"key":"3009_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","volume":"567","author":"MMS Obradovi\u0107","year":"2019","unstructured":"Obradovi\u0107, M. M. S. et al. Glucocorticoids promote breast cancer metastasis. Nature 567, 540\u2013544 (2019).","journal-title":"Nature"},{"key":"3009_CR10","doi-asserted-by":"crossref","unstructured":"Karvonen, H., Barker, H., Kaleva, L., Niininen, W. & Ungureanu, D. Molecular mechanisms associated with ROR1-mediated drug resistance: crosstalk with Hippo-YAP\/TAZ and BMI-1 pathways. Cells 8, 812 (2019).","DOI":"10.3390\/cells8080812"},{"key":"3009_CR11","doi-asserted-by":"publisher","first-page":"112727","DOI":"10.18632\/oncotarget.22559","volume":"8","author":"C Henry","year":"2017","unstructured":"Henry, C., Hacker, N. & Ford, C. Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget 8, 112727\u2013112738 (2017).","journal-title":"Oncotarget"},{"key":"3009_CR12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.tranon.2018.07.010","volume":"11","author":"K Veskim\u00e4e","year":"2018","unstructured":"Veskim\u00e4e, K. et al. Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples reveals new candidates for targeted therapies. Transl. Oncol. 11, 1160\u20131170 (2018).","journal-title":"Transl. Oncol."},{"key":"3009_CR13","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266\u201317271 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3009_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep05811","volume":"4","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci. Rep. 4, 5811 (2014).","journal-title":"Sci. Rep."},{"key":"3009_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","volume":"50","author":"J-K Lee","year":"2018","unstructured":"Lee, J.-K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399\u20131411 (2018).","journal-title":"Nat. Genet."},{"key":"3009_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/stem.1035","volume":"30","author":"HR Siddique","year":"2012","unstructured":"Siddique, H. R. & Saleem, M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30, 372\u2013378 (2012).","journal-title":"Stem Cells"},{"key":"3009_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP\/TAZ at the roots of cancer. Cancer Cell 29, 783\u2013803 (2016).","journal-title":"Cancer Cell"},{"key":"3009_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1530\/JME-15-0142","volume":"57","author":"L Yin","year":"2016","unstructured":"Yin, L. et al. The pro-adhesive and pro-survival effects of glucocorticoid in human ovarian cancer cells. J. Mol. Endocrinol. 57, 61\u201372 (2016).","journal-title":"J. Mol. Endocrinol."},{"key":"3009_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","volume":"116","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc. Natl Acad. Sci. USA 116, 1370\u20131377 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3009_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield, K., Ackland, M. L., Ahmed, N. & Rice, G. E. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol. Oncol. 113, 143\u2013148 (2009).","journal-title":"Gynecol. Oncol."},{"key":"3009_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.humpath.2004.01.024","volume":"35","author":"C Faleiro-Rodrigues","year":"2004","unstructured":"Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., Ferreira, V. M. & Lopes, C. S. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum. Pathol. 35, 663\u2013669 (2004).","journal-title":"Hum. Pathol."},{"key":"3009_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbamem.2008.11.005","volume":"1788","author":"TA Martin","year":"2009","unstructured":"Martin, T. A. & Jiang, W. G. Loss of tight junction barrier function and its role in cancer metastasis. Biochim. Biophys. Acta 1788, 872\u2013891 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"3009_CR23","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res."},{"key":"3009_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neo.2017.04.002","volume":"19","author":"Y Klymenko","year":"2017","unstructured":"Klymenko, Y. et al. Heterogeneous cadherin expression and multicellular aggregate dynamics in ovarian cancer dissemination. Neoplasia 19, 549\u2013563 (2017).","journal-title":"Neoplasia"},{"key":"3009_CR25","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013).","journal-title":"Cancer Discov."},{"key":"3009_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/path.5356","volume":"250","author":"K Kaipio","year":"2020","unstructured":"Kaipio, K. et al. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR\/mTOR-PI3K\/aurora kinase inhibitors. J. Pathol. 250, 159\u2013169 (2020).","journal-title":"J. Pathol."},{"key":"3009_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000084614","volume":"60","author":"C Faleiro-Rodrigues","year":"2005","unstructured":"Faleiro-Rodrigues, C., Macedo-Pinto, I. M., Maia, S. S., Vieira, R. H. & Lopes, C. S. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol. Obstet. Invest. 60, 75\u201383 (2005).","journal-title":"Gynecol. Obstet. Invest."},{"key":"3009_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.2910580315","volume":"58","author":"AL Veatch","year":"1994","unstructured":"Veatch, A. L., Carson, L. F. & Ramakrishnan, S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int. J. Cancer 58, 393\u2013399 (1994).","journal-title":"Int. J. Cancer"},{"key":"3009_CR29","first-page":"517","volume":"123","author":"RGW Verhaak","year":"2013","unstructured":"Verhaak, R. G. W. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517\u2013525 (2013).","journal-title":"J. Clin. Invest."},{"key":"3009_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ygyno.2015.06.033","volume":"138","author":"EM Stringer-Reasor","year":"2015","unstructured":"Stringer-Reasor, E. M. et al. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol. Oncol. 138, 656\u2013662 (2015).","journal-title":"Gynecol. Oncol."},{"key":"3009_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s000660050027","volume":"175","author":"M Mariotta","year":"1999","unstructured":"Mariotta, M. et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther. Onkol. 175, 392\u2013396 (1999).","journal-title":"Strahlenther. Onkol."},{"key":"3009_CR32","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1021\/jm101505d","volume":"54","author":"Q Cai","year":"2011","unstructured":"Cai, Q. et al. A potent and orally active antagonist (SM-406\/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 54, 2714\u20132726 (2011).","journal-title":"J. Med. Chem."},{"key":"3009_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1535-7163.MCT-13-0798","volume":"13","author":"CA Benetatos","year":"2014","unstructured":"Benetatos, C. A. et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-\u03baB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13, 867\u2013879 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"3009_CR34","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","volume":"32","author":"JR Infante","year":"2014","unstructured":"Infante, J. R. et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 32, 3103\u20133110 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3009_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","volume":"144","author":"L Bai","year":"2014","unstructured":"Bai, L., Smith, D. C. & Wang, S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharm. Ther. 144, 82\u201395 (2014).","journal-title":"Pharm. Ther."},{"key":"3009_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1126\/science.270.5234.283","volume":"270","author":"RI Scheinman","year":"1995","unstructured":"Scheinman, R. I., Cogswell, P. C., Lofquist, A. K. & Baldwin, A. S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270, 283\u2013286 (1995).","journal-title":"Science"},{"key":"3009_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286\u2013290 (1995).","journal-title":"Science"},{"key":"3009_CR38","doi-asserted-by":"publisher","first-page":"13504","DOI":"10.1073\/pnas.94.25.13504","volume":"94","author":"K De Bosscher","year":"1997","unstructured":"De Bosscher, K. et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc. Natl Acad. Sci. USA 94, 13504\u201313509 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3009_CR39","doi-asserted-by":"publisher","first-page":"29291","DOI":"10.1074\/jbc.273.45.29291","volume":"273","author":"KA Sheppard","year":"1998","unstructured":"Sheppard, K. A. et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273, 29291\u201329294 (1998).","journal-title":"J. Biol. Chem."},{"key":"3009_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cncr.29783","volume":"122","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122, 588\u2013597 (2016).","journal-title":"Cancer"},{"key":"3009_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-35860-z","volume":"8","author":"B Thibault","year":"2018","unstructured":"Thibault, B. et al. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. Sci. Rep. 8, 1\u201312 (2018).","journal-title":"Sci. Rep."},{"key":"3009_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.tips.2013.07.003","volume":"34","author":"M Kadmiel","year":"2013","unstructured":"Kadmiel, M. & Cidlowski, J. A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34, 518\u2013530 (2013).","journal-title":"Trends Pharmacol. Sci."},{"key":"3009_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ygyno.2017.04.012","volume":"146","author":"JT Veneris","year":"2017","unstructured":"Veneris, J. T. et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol. Oncol. 146, 153\u2013160 (2017).","journal-title":"Gynecol. Oncol."},{"key":"3009_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0306-4530(96)00009-1","volume":"21","author":"G van der Pompe","year":"1996","unstructured":"van der Pompe, G., Antoni, M. H. & Heijnen, C. J. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. Psychoneuroendocrinology 21, 361\u2013374 (1996).","journal-title":"Psychoneuroendocrinology"},{"key":"3009_CR45","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jnci\/92.12.994","volume":"92","author":"SE Sephton","year":"2000","unstructured":"Sephton, S. E., Sapolsky, R. M., Kraemer, H. C. & Spiegel, D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl Cancer Inst. 92, 994\u20131000 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"3009_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.psyneuen.2015.01.010","volume":"53","author":"A Schrepf","year":"2015","unstructured":"Schrepf, A. et al. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology 53, 256\u2013267 (2015).","journal-title":"Psychoneuroendocrinology"},{"key":"3009_CR47","doi-asserted-by":"publisher","first-page":"D355","DOI":"10.1093\/nar\/gkp896","volume":"38","author":"M Kanehisa","year":"2010","unstructured":"Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355\u2013D360 (2010).","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03009-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03009-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03009-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:23:27Z","timestamp":1670253807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03009-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03009-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"790"}}